Home » Stocks » OSUR

OraSure Technologies, Inc. (OSUR)

Stock Price: $12.92 USD 0.06 (0.47%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $12.85 -0.07 (-0.54%) Jan 15, 7:13 PM
Market Cap 934.68M
Revenue (ttm) 158.53M
Net Income (ttm) -14.34M
Shares Out 71.54M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $12.92
Previous Close $12.86
Change ($) 0.06
Change (%) 0.47%
Day's Open 12.90
Day's Range 12.72 - 13.25
Day's Volume 697,927
52-Week Range 5.57 - 19.58

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 3 days ago

OraSure: Well Positioned Ex-Covid, Sell Side Missing The Organic Growth Drivers

GlobeNewsWire - 1 week ago

BETHLEHEM, Pa., Jan. 08, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2021 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. E...

GlobeNewsWire - 1 week ago

BETHLEHEM, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laborato...

GlobeNewsWire - 3 weeks ago

OTTAWA, Dec. 23, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and anal...

GlobeNewsWire - 3 weeks ago

BETHLEHEM, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today disclosed that th...

GlobeNewsWire - 1 month ago

BETHLEHEM, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr...

GlobeNewsWire - 1 month ago

BETHLEHEM, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in the fight against HIV, today announced its plans to commemorate World AIDS Day. On Tues...

GlobeNewsWire - 2 months ago

BETHLEHEM, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laborato...

Investors Business Daily - 2 months ago

A Relative Strength Rating upgrade for Orasure Technologies shows improving technical performance. The post Stock Upgrades: Orasure Technologies Shows Rising Relative Strength appeared first o...

Seeking Alpha - 2 months ago

OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

OraSure (OSUR) delivered earnings and revenue surprises of 114.29% and 11.38%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

Net T hird Q uarter R evenues of $ 48.0 M illion Increased 33 % Year-Over-Year, D riven by $ 18 . 4 M illion in S ales of O ral F luid C ollection D evices for COVID-19 M olecular T esting

GlobeNewsWire - 2 months ago

Second FDA EUA for the Subsidiary's Saliva Collection Devices Second FDA EUA for the Subsidiary's Saliva Collection Devices

Zacks Investment Research - 2 months ago

OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 2 months ago

OraSure receives emergency use authorization for OMNIgene. Keros Therapeutics initiates Phase 2 clinical trial for Myelodysplastic Syndromes.

GlobeNewsWire - 2 months ago

BETHLEHEM, Pa., Oct. 21, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2020 third quarter financial results and...

The Motley Fool - 2 months ago

The FDA granted Emergency Use Authorization for the company's at-home saliva collection device for coronavirus testing.

InvestorPlace - 2 months ago

OraSure Technologies (OSUR) is in the news Monday after announcing approval from the FDA for one of its devices sent OSUR stock soaring. The post OraSure Technologies News: Why OSUR Stock Is S...

Benzinga - 2 months ago

Shares of OraSure Technologies, Inc. (NASDAQ: OSUR) were advancing strongly Monday after the diagnostic company said its DNA Genotek subsidiary's saliva collection device used in COVID-19 test...

24/7 Wall Street - 2 months ago

OraSure Technologies Inc. (NASDAQ: OSUR) shares jumped to start off the week after the company announced an update from the U.S.

GlobeNewsWire - 2 months ago

BETHLEHEM, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory ...

Zacks Investment Research - 3 months ago

Investors need to pay close attention to OraSure (OSUR) stock based on the movements in the options market lately.

GlobeNewsWire - 3 months ago

BETHLEHEM, Pa., Sept. 24, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laborato...

GuruFocus - 4 months ago

A prominent Harvard epidemiologist and expert in disease testing thinks a cheap, daily, do-it-yourself test can be as effective as a vaccine at cutting coronavirus transmission, according to a...

GlobeNewsWire - 4 months ago

BETHLEHEM, Pa., Sept. 03, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laborato...

GlobeNewsWire - 4 months ago

BETHLEHEM, Pa., Aug. 27, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome labora...

Investors Business Daily - 4 months ago

A Relative Strength Rating upgrade for Orasure Technologies shows improving technical performance. The post Stocks With Rising Relative Price Strength: Orasure Technologies appeared first on ...

Seeking Alpha - 5 months ago

OraSure Technologies, Inc. (OSUR) CEO Steve Tang on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

OraSure (OSUR) delivered earnings and revenue surprises of -77.78% and -14.54%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

BETHLEHEM, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laborator...

GlobeNewsWire - 5 months ago

BETHLEHEM, Pa., July 31, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laborator...

Zacks Investment Research - 5 months ago

OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 5 months ago

2020 Second Quarter Earnings Conference Call Wednesday, August 5, 2020, 5:00 p.m. ET

PRNewsWire - 6 months ago

MORRISVILLE, N.C., June 17, 2020 /PRNewswire/ -- Metabolon, Inc., the global leader in metabolomics, and DNA Genotek, a subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), have collaborat...

GlobeNewsWire - 6 months ago

OTTAWA, June 17, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and an...

GlobeNewsWire - 7 months ago

BETHLEHEM, Pa., June 10, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory...

GlobeNewsWire - 7 months ago

The number of EUAs utilizing OraSure’s saliva collection products continues to grow The number of EUAs utilizing OraSure’s saliva collection products continues to grow

GlobeNewsWire - 7 months ago

BETHLEHEM, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announced the full exercise by the underwriters of their option...

GlobeNewsWire - 7 months ago

BETHLEHEM, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announced the pricing of an underwritten offering of 8,000,000 ...

GlobeNewsWire - 7 months ago

BETHLEHEM, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announced it has commenced an underwritten public offering of 8...

GlobeNewsWire - 7 months ago

Acquisition strengthens OraSure’s leadership position in HIV field Acquisition strengthens OraSure’s leadership position in HIV field

GlobeNewsWire - 7 months ago

BETHLEHEM, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory...

GlobeNewsWire - 7 months ago

OTTAWA, May 22, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and ana...

GlobeNewsWire - 7 months ago

ST. PAUL, Minn. and OAKLAND, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ: OSUR), and Nom Nom™, a direct-to-consumer pet healt...

GlobeNewsWire - 8 months ago

All Microbiome Services to be Unified under the Diversigen Brand

Seeking Alpha - 8 months ago

OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

Board Change Also Announced Board Change Also Announced

Zacks Investment Research - 8 months ago

OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 9 months ago

Other Board Changes Also Announced Other Board Changes Also Announced

GlobeNewsWire - 9 months ago

BETHLEHEM, Pa., April 06, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laborator...

About OSUR

OraSure Technologies, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antig... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Nov 12, 1986
CEO
Douglas Michels
Employees
472
Stock Exchange
NASDAQ
Ticker Symbol
OSUR
Full Company Profile

Financial Performance

In 2019, OSUR's revenue was $154.61 million, a decrease of -14.93% compared to the previous year's $181.74 million. Earnings were $16.66 million, a decrease of -18.34%.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for OSUR stock is "Buy." The 12-month stock price forecast is 18.86, which is an increase of 45.98% from the latest price.

Price Target
$18.86
(45.98% upside)
Analyst Consensus: Buy